Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03072875 · ClinicalTrials.gov registry record · NA
CAMS-RAS: for Suicide Prevention
A NA study of Suicide, sponsored by Evidence-Based Practice Institute, Seattle, WA.
- Completed
- Registry status
- NA
- Development phase
- 26
- Enrollment target
- 1
- Study location
NCT03072875: Completed NA study of Suicide, sponsored by Evidence-Based Practice Institute, Seattle, WA.
NCT03072875 is a NA study of Suicide that has completed, run by Evidence-Based Practice Institute, Seattle, WA. The registered enrollment target is 26 participants, below the 6,990-participant average among 92 other Suicide trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03072875, a NA study of Suicide, has completed, sponsored by Evidence-Based Practice Institute, Seattle, WA.
- COMPLETED
- Registry status
- NA
- Development phase
- 26 participants
- Enrollment target
- 1
- Study location
Study Summary
This Phase I feasibility study endeavors to create a prototype of a tool to determine its feasibility with suicidal patients in emergency departments (EDs). This is not a clinical trial. The overarching goal of this research is to create a tool that could reduce suicide rates, increase delivery of efficacious suicide interventions, and decrease overall costs associated with suicidal behaviors. SBIR Phase I project aims include: (1) creating an advisory board to guide the development of CAMS-RAS; (2) iteratively design and develop relational agent ("Dr. Dave") modeled after the gestures, expressions, and mannerisms of CAMS treatment developer, David Jobes, PhD; and (3) conduct feasibility tests to determine whether CAMS-RAS is acceptable, easy to use, and liked by target end-users: acutely suicidal patients admitted to hospital EDs, psychiatric inpatient units, and medical floors for treatment of injuries sustained during a suicide attempt; hospital medical personnel, administrators, and other stakeholders including peer advocates; and outpatient suicidal patients, clinicians and administrators.
Primary Outcome
A brief face-valid, self-report measure that the PI derived from the System Usability Scale and has been successfully used in previous studies. Items are rated on a 5-point Likert Scale (1=poor; 3=good; 5=excellent). Includes open-ended questions to better understand what was most and least helpful with respect to each category and also measures users' acceptance.
Conditions Studied
Interventions
- DEVICE CAMS-RAS
Study Locations (1)
Washington
- Evidence-Based Practice Institute - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2015-12-18 |
| Est. Completion | 2017-12-17 |
| Phase | NA |
What the finished NCT03072875 record still lists
NCT03072875 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 6,990-participant average among 92 other Suicide trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Suicide appearing as the primary indexed condition, and to 1 intervention - of which CAMS-RAS is the first listed.
NCT03072875 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT03072875 about?
NCT03072875 is a clinical study titled "CAMS-RAS: for Suicide Prevention". This Phase I feasibility study endeavors to create a prototype of a tool to determine its feasibility with suicidal patients in emergency departments (EDs). This is not a clinical trial. The overarching goal of this research is to create a tool that could reduce suicide rates, increase delivery of e...
What is the current status of trial NCT03072875?
This trial is currently completed. It is a NA study. The enrollment target is 26 participants. The study started on 2015-12-18. Estimated completion is 2017-12-17.
What conditions does trial NCT03072875 study?
This clinical trial studies the following conditions: Suicide.
What interventions are being tested in trial NCT03072875?
The interventions under investigation include: CAMS-RAS (DEVICE).
Who is sponsoring clinical trial NCT03072875?
This trial is sponsored by Evidence-Based Practice Institute, Seattle, WA, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03072875 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Suicide
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03072875's enrollment target sits among peer trials
26 83rd of 92 higher than 9 of 92 other Suicide trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Suicide trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Reaching Out to Distressed Medical Residents, Fellows and Faculty
RECRUITING · NA
-
Randomized Clinical Trial of Supplementing Brief Psychotherapy With a Mobile App
RECRUITING · NA
-
Reducing Suicide Risk Among Aging Caregivers of Persons With AD/ADRD
RECRUITING · NA
-
Functional Connectivity Alterations in Suicidal Patients Among Opioid Users
RECRUITING · NA
-
Suicide Specific Rumination in Veterans
RECRUITING · NA
-
Real-time Examination of Skills and Coping Use in Teen's Everyday Lives
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI